The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...
UPPSALA, SE / ACCESS Newswire / March 18, 2026 /Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...
Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...
A nationwide cohort study in Taiwan found a higher risk of psoriasis in cancer patients treated with immune checkpoint inhibitors compared to other therapies. The study analyzed data from 3,188 ...
Immune checkpoint inhibitors, designed to block tumors from weakening the body’s immune activity, have been found to interfere with immune regulation in the heart. This side effect may lead to an ...
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results